Andrea Lobo, PhD,  science writer—

All eligible cystic fibrosis (CF) patients in England can now receive Vertex Pharmaceuticals’ CF treatment Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), after the company reached a reimbursement agreement with the National Health Service (NHS). The decision follows a positive recommendation from the National Institute for Health and Care Excellence and the treatment’s…

More than a third of caregivers of children with cystic fibrosis (CF) reported delays in getting information about the diagnosis after a positive newborn screening (NBS) test for the disease, according to a study in the U.S. Caregivers mentioned delays in receiving their child’s CF diagnosis and in…

The Cystic Fibrosis Foundation (CFF) has awarded $5 million to the Cleveland Clinic to continue as the biorepository coordinating center for the Cystic Fibrosis Lung Transplant Consortium until 2030, supporting research and other efforts to improve lung transplant outcomes. Created in 2017, the consortium has established a…

The Clairity Ball — the hallmark annual event of Claire’s Place Foundation — is set to return to Southern California later this month with an evening of fundraising that will bring together celebrities and champions of the cystic fibrosis (CF) community. The nonprofit’s May 31 ball, to…

The events slated for this year’s Cystic Fibrosis Awareness Month aim to celebrate the accomplishments, milestones, and hopes of those in the cystic fibrosis (CF) community. During May, U.S. and international organizations are encouraging people with CF to share their experiences and challenges, helping others picture what the future…

Children and adolescents with cystic fibrosis (CF) treated with Kaftrio, marketed as Trikafta in the U.S., experienced increases in the fat-soluble vitamins D and A for up to one year, according to a study from Spain. Treatment reduced the proportion of participants with vitamin D and vitamin A…

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) contributed to a reduction in pulmonary exacerbations requiring hospitalization between 2018 and 2022 among children and young adults with cystic fibrosis (CF). That’s according to a recent study in the U.S. that also demonstrated that the proportion of hospitalized CF patients from minority groups,…

Researchers at the University of California, Los Angeles (UCLA) are developing a gene-editing therapy — designed to be delivered as a one-time inhalable treatment — that aims to correct the underlying mutations that cause cystic fibrosis (CF). The team is using tiny fat-based particles to deliver the gene-editing machinery…

Poor sleep quality is linked to a higher risk of malnutrition in adolescents with cystic fibrosis (CF), suggesting that sleep disturbances may contribute to added nutritional challenges in these patients, a study in Turkey shows. The effects weren’t influenced by patients’ body mass index (BMI) percentile, a measure of…

Discoveries into the process underlying protein organization on cell membranes could ultimately lead to new ways to treat cystic fibrosis (CF), according to a study from Canada that shed light on some of the mechanisms underlying the disease. The study found that proteins linked to CF organize themselves into clusters…